

Incyte appoints new CSO

28 November 2018 | News

Dr. Dhanak will succeed Dr. Reid Huber, who has been at Incyte since 2002 and is leaving the Company to pursue opportunities in the early-stage life sciences community



Pharma company, Incyte has announced the appointment of Dashyant Dhanak as Executive Vice President and Chief Scientific Officer, effective December 10, 2018.

Dr. Dhanak will succeed Dr. Reid Huber, who has been at Incyte since 2002 and is leaving the Company to pursue opportunities in the early-stage life sciences community.

Hervé Hoppenot, Chief Executive Officer, Incyte said, “Reid’s contributions to Incyte have been instrumental in its evolution from a start-up operation to the world-class discovery engine of today, and I thank him most sincerely for his commitment and critical thinking over the last 16 years. Reid’s decision to pursue a different career path has given us the opportunity to recruit a new leader for our discovery team, and Dash brings an ideal mix of discovery and development experience into what I believe is the most innovative and productive group in the industry.”

Dr. Dhanak joins Incyte from Janssen Research & Development and prior to Janssen, he spent 25 years at GlaxoSmithKline.